Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Lawrence P, Carter"'
Autor:
Lawrence C. Carter, Ben J. Williamson
Publikováno v:
Frontiers in Earth Science, Vol 12 (2024)
Porphyry-type Cu ± Au ± Mo deposits form in the upper (ca. 2–5 km deep) parts of large, long-lived magmatic-hydrothermal systems in which mineralising fluids are thought to be derived from mid-to shallow-crustal magma chambers. Increasingly, howe
Externí odkaz:
https://doaj.org/article/b8d9b33aebe44b74bba46fc47e2ec801
Autor:
Michael Ward, Lawrence P. Carter, Julie Y. Huang, Daniel Maslyar, Balasubrahmanyam Budda, Robert Paul, Arnon Rosenthal
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 10, Iss 1, Pp n/a-n/a (2024)
Abstract INTRODUCTION Heterozygous mutations in the GRN gene lead to reduced progranulin (PGRN) levels in plasma and cerebrospinal fluid (CSF) and are causative of frontotemporal dementia (FTD) with > 90% penetrance. Latozinemab is a human monoclonal
Externí odkaz:
https://doaj.org/article/dd511265638b4ca39288d8acd272d8a6
Autor:
Lawrence C. Carter, Simon R. Tapster, Ben J. Williamson, Yannick Buret, David Selby, Gavyn K. Rollinson, Ian Millar, Daniel B. Parvaz
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-20 (2022)
Abstract Porphyry-type deposits are a vital source of green technology metals such as copper and molybdenum. They typically form in subduction-related settings from large, long-lived magmatic systems. The most widely accepted model for their formatio
Externí odkaz:
https://doaj.org/article/c2db51f5694847769d13ebd5b514adc4
Autor:
Jaime K. Devine, Lindsay Schwartz, Steven Hursh, Jerryll Asin, Nicolaas de Vries, Patty E. Vonk, Annemiek Vermeeren, Claire E. H. M. Donjacour, Frederick Vinckenbosch, Johannes G. Ramaekers, Hennie Janssen, Grace Wang, Dan Chen, Lawrence P. Carter, Sebastiaan Overeem, Gert Jan Lammers
Publikováno v:
NEUROLOGY AND THERAPY. SPRINGER LONDON LTD
NEUROLOGY AND THERAPY
Neurology and Therapy, 12(1), 249-265. Springer Healthcare
Neurology and Therapy
Neurology and Therapy, 12(1), 249-265. Springer
Devine, J K, Schwartz, L, Hursh, S, Asin, J, de Vries, N, Vonk, P E, Vermeeren, A, Donjacour, C E H M, Vinckenbosch, F, Ramaekers, J G, Janssen, H, Wang, G, Chen, D, Carter, L P, Overeem, S & Lammers, G J 2023, ' Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions ', Neurology and Therapy, vol. 12, no. 1, pp. 249-265 . https://doi.org/10.1007/s40120-022-00425-w
NEUROLOGY AND THERAPY
Neurology and Therapy, 12(1), 249-265. Springer Healthcare
Neurology and Therapy
Neurology and Therapy, 12(1), 249-265. Springer
Devine, J K, Schwartz, L, Hursh, S, Asin, J, de Vries, N, Vonk, P E, Vermeeren, A, Donjacour, C E H M, Vinckenbosch, F, Ramaekers, J G, Janssen, H, Wang, G, Chen, D, Carter, L P, Overeem, S & Lammers, G J 2023, ' Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions ', Neurology and Therapy, vol. 12, no. 1, pp. 249-265 . https://doi.org/10.1007/s40120-022-00425-w
INTRODUCTION: Excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) can impair vigilance/attention. Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved to treat EDS associated with narcolep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96676d42a2bc228eabf424ae1ab5c4d7
https://hdl.handle.net/1887/3505726
https://hdl.handle.net/1887/3505726
Autor:
Frederick Vinckenbosch, Jerryll Asin, Nicolaas de Vries, Patty E. Vonk, Claire E. H. M. Donjacour, Gert Jan Lammers, Sebastiaan Overeem, Hennie Janssen, Grace Wang, Dan Chen, Lawrence P. Carter, Kefei Zhou, Annemiek Vermeeren, Johannes G. Ramaekers
Publikováno v:
Human psychopharmacology: clinical and experimental
Human psychopharmacology, 37(6):e2845
Human Psychopharmacology, 37(6):e2845. Wiley
Human Psychopharmacology: Clinical and Experimental, 37(6). WILEY
Human psychopharmacology, 37(6):e2845
Human Psychopharmacology, 37(6):e2845. Wiley
Human Psychopharmacology: Clinical and Experimental, 37(6). WILEY
OBJECTIVE: To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on-the-road driving in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea (OSA).METHODS: Eligible parti
Autor:
Frederick Vinckenbosch, Gert Jan Lammers, Sebastiaan Overeem, Dan Chen, Grace Wang, Lawrence P. Carter, Kefei Zhou, Johannes G. Ramaekers, Annemiek Vermeeren
Publikováno v:
Human Psychopharmacology: Clinical and Experimental, 38(1). WILEY
Human Psychopharmacology, 38(1):e2858. Wiley
Human Psychopharmacology-Clinical and Experimental, 38(1):e2858. Wiley
Human Psychopharmacology, 38(1):e2858. Wiley
Human Psychopharmacology-Clinical and Experimental, 38(1):e2858. Wiley
OBJECTIVE: To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on-the-road driving performance in participants with narcolepsy.METHODS: In this randomised, double-blind, placebo-controlled, crossover study, dr
Publikováno v:
Clinical Pharmacology in Drug Development
Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, is approved (United States and European Union; Sunosi) to treat excessive daytime sleepiness associated with narcolepsy (75‐150 mg/day) or obstructive sleep apnea (37.5‐150 mg/day).
Autor:
John D. Hudson, Richard K. Bogan, Heike Benes, Dan Chen, Thomas Stern, Lawrence Lee, Stephen G. Thein, Morgan Bron, Jed Black, Terri E. Weaver, Christopher L. Drake, James Maynard, James M. Andry, Lawrence P. Carter
Publikováno v:
Annals of the American Thoracic Society
Rationale: Excessive daytime sleepiness in patients with obstructive sleep apnea is associated with substantial burden of illness. Objectives: To assess treatment effects of solriamfetol, a dopamine/norepinephrine reuptake inhibitor, on daily functio
Publikováno v:
J Clin Sleep Med
STUDY OBJECTIVES: To explore knowledge and experiences of women with narcolepsy on pregnancy and contraception issues and their relationships with narcolepsy pharmacotherapy. METHODS: An 18-item survey was administered through the Narcolepsy Network
Autor:
Michael J. Thorpy, Giuseppe Plazzi, Geert Mayer, Colin M. Shapiro, Yves Dauvilliers, Lawrence P. Carter, Bruce C. Corser, Jed Black, Helene A. Emsellem, Yuan Lu, Hao Wang, Dan Chen
Publikováno v:
Annals of Neurology. 85:359-370
Objective Solriamfetol (JZP‐110) is a selective dopamine and norepinephrine reuptake inhibitor with wake‐promoting effects. This phase 3 study ({"type":"clinical-trial","attrs":{"text":"NCT02348593","term_id":"NCT02348593"}}NCT02348593) evaluated